Abionyx Looks To Next Steps As Renal Sepsis Candidate Succeeds At Phase IIa
Seeking Partnerships And Fundraising
The French firm’s lead asset has impressed in a Phase IIa trial in sepsis patients at risk of kidney injury, triggering discussions with regulators for a path forward in the challenging and life-threatening condition.
You may also be interested in...
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.
Recent executive moves in the industry include C-suite changes at Fresh Tracks Therapeutics and Protara Therapeutics. Meanwhile, new directors were appointed at Grey Wolf Therapeutics and BioSenic.
The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.